Clinical Trial Search

Primary: Patient Reported Outcomes Measurement Information System (PROMIS) Upper Extremity — 39; 43; 41 T-score

Primary: Duration of the First "Off-treatment" Cycle in Patients Who Have Completed One Cycle of Intermittent Androgen Suppression With the Addition of Exisulind. — 39 Weeks

Primary: Change From Baseline in PRA — -0.706; -2.176; -1.688; -2.353 percentage of population — p=0.324

Primary: Mean Change in Total Meibomian Gland Score — 12.8; 1.9 Change in Meibomian Gland Score

Primary: Mean Combined Score (CS) Consisting of TRSS/8+Allergy Medication Score[AMS]) — 1.99; 1.91; 1.93 units on a scale

Primary: Blood Glucose Values (More Than One ) > 180 mg% — 17; 33 Participants — p=0.001

Primary: Global Hemostatic Efficacy Assessment Score (GHEA) - Composed of 3 Individual Ratings — 100.0; 100.0; 100.0; 100.0 Percentage of surgeries

Primary: Time to Androgen Independence of Serum Prostate-Specific Antigen (PSA) — 4.0 years

Primary: Percentage of Participants Without Recurrent Clinical Symptoms of an Incompetent Greater Saphenous Vein After Treatment. — 79.3; 77.5 percentage of total participants

Primary: Change in Adult ADHD Investigator Symptom Rating Scale (AISRS) Score — -6.3 units on a scale

Primary: Opioid Use — 101.24; 104.56 morphine equivalent dose

Primary: Mean Combined Score in Cat-PAD Treatment Groups Compared With Placebo — 1.04; 1.00; 1.05 units on a scale

Primary: Kaplan Meier Estimate of Progression-Free Survival (PFS) Based on Food and Drug Administration (FDA) Methodology — 2.9; 4.0 months — p=0.1789

Primary: Change From Baseline in American Urological Association Symptom Score — -14.7; -10.5 units on a scale

Primary: Number of Participants With Peripheral Neuropathy — 1; 15 participants